Back to Newsroom
Back to Newsroom

CLASS-ACTION-UPDATE-for-NTRA-ARQQ-and-UPST-Levi-&-Korsinsky-LLP-Reminds-Investors-of- Class-Actions-on-Behalf-of-Shareholders

Wednesday, 18 May 2022 02:10 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 18, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NTRA Shareholders Click Here: https://www.zlk.com/pslra-1/natera-inc-loss-submission-form?prid=27432&wire=1
ARQQ Shareholders Click Here: https://www.zlk.com/pslra-1/arqit-quantum-inc-f-k-a-centricus-acquisition-corp-loss-submission-form?prid=27432&wire=1
UPST Shareholders Click Here: https://www.zlk.com/pslra-1/upstart-inc-loss-submission-form?prid=27432&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, May 18, 2022, Press release picture

Natera, Inc. (NASDAQ:NTRA)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
Lead Plaintiff Deadline : June 27, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/natera-inc-loss-submission-form?prid=27432&wire=1

According to the filed complaint, (1) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.

Arqit Quantum Inc. f/k/a Centricus Acquisition Corp. (NASDAQ:ARQQ)

This lawsuit is on behalf of: (i) all persons or entities who purchased or otherwise acquired Arqit securities between September 7, 2021 and April 18, 2022, inclusive; and/or (ii) all holders of Centricus securities as of the record date for the special meeting of shareholders held on August 31, 2021 to consider approval of the merger between Arqit and Centricus (the "Merger") and entitled to vote on the Merger.
Lead Plaintiff Deadline : July 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/arqit-quantum-inc-f-k-a-centricus-acquisition-corp-loss-submission-form?prid=27432&wire=1

According to the filed complaint, (1) Arqit's proposed encryption technology would require widespread adoption of new protocols and standards for telecommunications; (2) British cybersecurity officials questioned the viability of Arqit's proposed encryption technology in a meeting in 2020; (3) the British government was not an Arqit customer but, rather, providing grants to Arqit; (4) Arqit had little more than an early-stage prototype of its encryption system at the time of the Merger; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Upstart, Inc. (NASDAQ:UPST)

UPST Lawsuit on behalf of: investors who purchased November 9, 2021 - May 9, 2022
Lead Plaintiff Deadline : July 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/upstart-inc-loss-submission-form?prid=27432&wire=1

According to the filed complaint, during the class period, Upstart, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Upstart's AI model could not adequately account for macroeconomic factors such as interest rates that impact the market-clearing price for loans; (2) as a result, Upstart was experiencing a negative impact on its conversion rate; (3) as a result, the Company was reasonably likely to use its balance sheet to fund loans; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: